Protective Effects of Metformin and Rosiglitazone on Cardiac Dysfunction in Experimental Diabetic Cardiomyopathy Model Rats / 世界科学技术-中医药现代化

ABSTRACT

This study was aimed to compare and investigate protective effects of metformin and rosiglitazone on cardiac dysfunction in experimental diabetic cardiomyopathy (DC) model rats. The experimental DC rat model was induced by feeding high calorie diet plus single intraperitoneal injection of small dosage of streptozotocin (STZ). Then, intragastric administration of metformin (140 mg·kg-1) or rosiglitazone(2 mg·kg-1) was given to DC rats for consecutive 6 weeks. Parameters of general signs, eating amount, blood sugar, blood lipids, heart function, heart structure and lipometabolism of myocardial tissues were measured. The results showed that both metformin and rosiglitazone can obviously improve the myocardial injury of DC model rats and reduce the CK value (P < 0.01). Metformin can obviously increase the cardiac output of DC model rats (P < 0.01). Rosiglitazone can improve the maximum rate of myocardial contraction and diastole of the model rat's left ventricle (P < 0.05). Both metformin and rosiglitazone can decrease interventricular septal thickness (IST) value (P < 0.01). Metformin can obviously im-prove general signs of DC rats, inhibit body weight loss and reduce water intake (P < 0.05). Metformin can obvi-ously reduce the blood sugar level (FBG, GSP, HbA1c and FMN) of DC rats (P < 0.05, or P < 0.01) as well as the concentration of TG (P < 0.01). Rosiglitazone can reduce the concentration of FBG and HbA1c (P < 0.05). Meanwhile, rosiglitazone can significantly reduce the concentration of TG and LDL as well as obviously increase the myocardial FA-β-oxidase (P < 0.05). It was concluded that both metformin and rosiglitazone can recover the cardiac dysfunction and myocardial injury of DC rats on certain level. Metformin showed more effects on eating amount and body weight improvements of DC rats.